CD154 has shown promise - in a phase I/IIa trial of patients with urothelial carcinoma of the bladder, intravesicular adenovirus carrying CD154 led to absence of tumor on cystectomy in 3 out of 5 patients with high risk cancer with plans for cystectomy, and to tumor shrinkage in 1 out of 3 patients who had stage Ta tumors [97]. Here, CD40LG is linked to neoplasm.